FDA To Review Vytorin Data: ENHANCEd Label To Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will assess why lower LDL did not mean less arterial plaque in the trial.
You may also be interested in...
GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib
GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early
GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib
GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early
FDA’s Change Of Heart On Vytorin Ads
Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.